PCIB PCI Biotech Holding ASA

PCI Biotech Holding ASA: Annual Report 2022

PCI Biotech Holding ASA: Annual Report 2022

Oslo, Norway, April 28, 2023



The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2022. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2022 is also available on the company’s website

For further information, please contact:        

PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                

Ronny Skuggedal, CEO, , Mobile:  757

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments



EN
28/04/2023

Underlying

PCIBPCI Biotech Holding ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

Notice of Extraordinary General Meeting, proposed company dissolution ...

Notice of Extraordinary General Meeting, proposed company dissolution and delisting Oslo, Norway 23 February 2026 – An extraordinary general meeting of PCI Biotech Holding ASA (‘PCI Biotech’ or ‘Company’) will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 16 March 2026 at 10:00am (CET). The proposed resolutions include company dissolution and delisting from Euronext Oslo Børs. The Board of Directors’ proposed resolution to dissolve PCI Biotech is made as there is no longer any operational activity in the Company, nor is it expected that it will resume such acti...

February 23, 2026 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech initiates a process to evaluate the opportunity for a stru...

PCI Biotech initiates a process to evaluate the opportunity for a structured wind-up process Oslo (Norway), 29 January 2026 – PCI Biotech (OSE: PCIB) refers to its latest announcement of 8 January 2026 regarding the discontinuation of all R&D operations and the continued exploration of strategic alternatives. This evaluation has now been concluded. Following careful consideration of the PCI Biotech group’s circumstances, the Board has resolved to initiate a process to evaluate the opportunity for a structured wind-up. The liquidity position of the PCI Biotech group remains critical, casti...

January 29, 2026 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech announces discontinuation of R&D operations and continues ...

PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options Oslo (Norway), 8 January 2026 – PCI Biotech (OSE: PCIB). Reference is made to the company’s latest announcement dated 23rd October 2025. The external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration. As PCI Biotech’s limited operations were contingent upon sustained external interest, all R&D operations will now be discontinued. In recent months, various strategic alternatives have been explored, and this process continues. The evalu...

January 8, 2026 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech update

PCI Biotech update Oslo (Norway), 23 October 2025 – PCI Biotech (OSE: PCIB) today provides an update on the ongoing evaluation of its operations.  Reference is made to the company’s announcements dated 18th August 2025 and 25th September 2025, as well as the interim report for the first half of 2025 published on 29th August 2025. As previously communicated, current activities are focused on the evaluation of a new bioprocessing technology by an undisclosed party, conducted under a material transfer agreement without financial terms. The company’s limited operations and the group’s future...

October 23, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech update on future operations

PCI Biotech update on future operations Oslo (Norway), 25 September 2025 – PCI Biotech (OSE:PCIB) today announces an update on the ongoing evaluation of its future operations. Reference is made to the announcement on 18th August 2025 regarding the discontinuation of further development of the PCL technology. The decision was based on insufficient progress, which extended project timelines and increased resource requirements, elevating the overall project risk to an unacceptable level. Consequently, PCI Biotech decided to discontinue further development. PCI Biotech's immediate priority ha...

September 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch